MiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow MDXG
MiMedx Group, Inc (MDXG) Piotroski F-score
MiMedx Group, Inc's Piotroski F-score for fiscal 2025 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 5 | 0.00 |
| FY2024 | 5 | (2.00) |
| FY2023 | 7 | 5.00 |
| FY2022 | 2 | (2.00) |
| FY2021 | 4 | 1.00 |
| FY2020 | 3 | 1.00 |
| FY2019 | 2 | (3.00) |
| FY2018 | 5 | 0.00 |
| FY2017 | 5 | 1.00 |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 16.02% | 16.87% | Pass | 1 |
| Positive operating cash flow | 74.00m | 66.20m | Pass | 1 |
| Rising return on assets | 16.02% | 16.87% | Fail | 0 |
| Cash flow above net income | 25.43m | 23.78m | Pass | 1 |
| Falling long-term leverage | 0.05 | 0.07 | Pass | 1 |
| Rising current ratio | 4.32 | 4.21 | Pass | 1 |
| No new shares issued | 147,793,100 | 146,979,400 | Fail | 0 |
| Rising gross margin | 82.56% | 82.78% | Fail | 0 |
| Rising asset turnover | 1.38 | 1.39 | Fail | 0 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| MDXG MiMedx Group, Inc | 5 |
| PHAR Pharming Group N.V. Sponsored ADR compare | 5 |
| GYRE Gyre Therapeutics, Inc. compare | 4 |
| OABI OmniAb, Inc. compare | 2 |
| CADL Candel Therapeutics, Inc. compare | 1 |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | — |
| DSGN Design Therapeutics, Inc. compare | — |
| ANNX Annexon, Inc. compare | — |
| AURA Aura Biosciences, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover